GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Cyclically Adjusted PB Ratio

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Cyclically Adjusted PB Ratio : 4.49 (As of Apr. 29, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-29), ACADIA Pharmaceuticals's current share price is $17.10. ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $3.81. ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 4.49.

The historical rank and industry rank for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

ACAD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.96   Med: 13.23   Max: 27.83
Current: 4.39

During the past years, ACADIA Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 27.83. The lowest was 3.96. And the median was 13.23.

ACAD's Cyclically Adjusted PB Ratio is ranked worse than
75.51% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs ACAD: 4.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $2.622. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.81 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.99 19.15 7.13 4.32 8.22

ACADIA Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.32 4.99 6.30 5.45 8.22

Competitive Comparison of ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=17.10/3.81
=4.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.622/129.4194*129.4194
=2.622

Current CPI (Dec. 2023) = 129.4194.

ACADIA Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.698 99.695 4.801
201406 3.526 100.560 4.538
201409 3.315 100.428 4.272
201412 3.093 99.070 4.041
201503 2.843 99.621 3.693
201506 2.545 100.684 3.271
201509 2.253 100.392 2.904
201512 1.960 99.792 2.542
201603 3.948 100.470 5.086
201606 3.596 101.688 4.577
201609 4.773 101.861 6.064
201612 4.271 101.863 5.426
201703 3.751 102.862 4.719
201706 3.393 103.349 4.249
201709 3.075 104.136 3.822
201712 2.695 104.011 3.353
201803 2.437 105.290 2.996
201806 2.118 106.317 2.578
201809 1.787 106.507 2.171
201812 3.330 105.998 4.066
201903 2.903 107.251 3.503
201906 2.692 108.070 3.224
201909 4.489 108.329 5.363
201912 4.503 108.420 5.375
202003 4.107 108.902 4.881
202006 4.213 108.767 5.013
202009 4.122 109.815 4.858
202012 3.928 109.897 4.626
202103 3.631 111.754 4.205
202106 3.517 114.631 3.971
202109 3.528 115.734 3.945
202112 3.359 117.630 3.696
202203 2.756 121.301 2.940
202206 2.687 125.017 2.782
202209 2.630 125.227 2.718
202212 2.471 125.222 2.554
202303 2.305 127.348 2.342
202306 2.423 128.729 2.436
202309 2.209 129.860 2.202
202312 2.622 129.419 2.622

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ACADIA Pharmaceuticals  (NAS:ACAD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Executives
Austin D. Kim officer: EVP & General Counsel C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan officer: EVP, COO, Head of Commercial C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis director, officer: PRESIDENT AND CEO ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara officer: Principal Accounting Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer officer: Chief Financial Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson officer: Executive VP, Research & Dev AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic officer: EVP C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff officer: EVP and CFO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang officer: EVP AND CCO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller officer: Controller & PAO C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Headlines